Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1521742 | 0.97 | CA1 (0.52) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL13058300 | 0.97 | CA1 (0.52) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL1439330 | 0.97 | CA1 (0.52) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL12097565 | 0.94 | — | — | |
| SCHEMBL24997068 | 0.87 | POLB (0.52) | POLBTSHRL3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL8341632 | 0.87 | POLB (0.52) | POLBTSHRL3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL28242652 | 0.87 | — | — | |
| SCHEMBL28195299 | 0.84 | L3MBTL1 (0.42) | POLBTSHRKMT2AHPGDL3MBTL1 | |
| SCHEMBL178417 | 0.84 | L3MBTL1 (0.49) | TSHRKMT2AL3MBTL1GAAALDH1A1 | |
| SCHEMBL4277869 | 0.82 | L3MBTL1 (0.47) | CA1CA2POLBTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0074894-B1 | PROCESS FOR THE PURIFICATION OF A GASEOUS MIXTURE CONTAINING UNDESIRABLE GASEOUS COMPOUNDS | COMPAGNIE FRANCAISE DE RAFFINAGE Société anonyme dite: (FR) | 1985-01-02 | — | — | EP | claimed |
| EP-0074894-A1 | Process for the purification of a gaseous mixture containing undesirable gaseous compounds | COMPAGNIE FRANCAISE DE RAFFINAGE Société anonyme dite: (FR) | 1983-03-23 | — | — | EP | claimed |
| US-4170547-A | SOLVENT EXTRACTION | COMPAGNIE FRANCAISE DE RAFFINAGE (FR) | 1979-10-09 | — | — | US | claimed |
| US-20230286968-A1 | ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| EP-4023647-A1 | IMIDAZOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | TSD Life Sciences Co., Ltd. (KR) | 2022-07-06 | — | — | EP | disclosed |
| EP-4006028-A1 | IRAK4 KINASE INHIBITOR AND PREPARATION METHOD THEREFOR | Zhuhai Yufan Biotechnologies Co., Ltd (CN) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021018012-A1 | IRAK4 KINASE INHIBITOR AND PREPARATION METHOD THEREFOR | 珠海宇繁生物科技有限责任公司 | 2021-02-04 | — | — | WO | disclosed |
| US-10888554-B2 | Salts of heterocyclic modulators of HIF activity for treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-01-12 | — | — | US | disclosed |
| US-20200171017-A1 | SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-06-04 | — | — | US | disclosed |
| US-9676757-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
| US-20070123711-A1 | Synthesis methods and intermediates for the manufacture of rizatriptan | RATIOPHARM GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
| US-20070123711-A1 | Synthesis methods and intermediates for the manufacture of rizatriptan | RATIOPHARM GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
| WO-2004082687-A1 | LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | disclosed |
| EP-0464838-B1 | Substituted sulfonylalkylsulfonylureas, process for their preparation and their use as herbicides and plant growth regulators | HOECHST SCHERING AGREVO GMBH (DE) | 1998-10-07 | — | — | EP | disclosed |
| US-5223017-A | SUBSTITUTED SULFONYLALKYLSULFONYLUREAS AND THEIR USE AS HERBICIDES AND PLANT GROWTH REGULATORS | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-06-29 | — | — | US | disclosed |
| EP-0464838-A2 | Substituted sulfonylalkylsulfonylureas, process for their preparation and their use as herbicides and plant growth regulators | Hoechst Schering AgrEvo GmbH (DE) | 1992-01-08 | — | — | EP | disclosed |
| EP-0074894-B1 | PROCESS FOR THE PURIFICATION OF A GASEOUS MIXTURE CONTAINING UNDESIRABLE GASEOUS COMPOUNDS | COMPAGNIE FRANCAISE DE RAFFINAGE Société anonyme dite: (FR) | 1985-01-02 | — | — | EP | disclosed |
| EP-0074894-A1 | Process for the purification of a gaseous mixture containing undesirable gaseous compounds | COMPAGNIE FRANCAISE DE RAFFINAGE Société anonyme dite: (FR) | 1983-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200171017-A1 | SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, VHL, HIF1A | CA1 420/4885CA2 87/4885POLB 1604/4885 |
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | HSD17B1, HSD17B13, HSD17B3 | CA1 1353/4885CA2 2183/4885POLB 1547/4885 |
| US-20070123711-A1 | Synthesis methods and intermediates for the manufacture of rizatriptan | HTR7, HRH4, CA7 | CA1 85/4885CA2 56/4885POLB 2884/4885 |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | JAK1, JAK3, MAP3K4 | CA1 4881/4885CA2 4789/4885POLB 1025/4885 |
| US-10888554-B2 | Salts of heterocyclic modulators of HIF activity for treatment of disease | HIF1AN, VHL, HIF1A | CA1 420/4885CA2 87/4885POLB 1604/4885 |
| US-20230286968-A1 | ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP4B1, CYP1B1 | CA1 4772/4885CA2 4868/4885POLB 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.